Pfizer Inc. (PFE)
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked
Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's valuation at 9x 2025 EPS and a 6.5% dividend yield make it attractive for long-term investors. Management's 2025 guidance indicates flat sales but improved profitability, with gross margins expected to reach the upper 70s, enhancing shareholder value and supporting its strong dividend payouts.
Pfizer Just Reassured Investors, but Is the Stock a Buy?
Amid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer (PFE 2.29%) is communicating that everything is under control. Per its updated forecast for its 2024 and 2025 fiscal years on Dec. 17, the overarching message is that the pharma will continue to seek to control its costs while bolstering its portfolio of medicines as usual.
Why Pfizer (PFE) Dipped More Than Broader Market Today
Pfizer (PFE) concluded the recent trading session at $25.77, signifying a -0.46% move from its prior day's close.
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?
Shares of Pfizer (PFE -2.04%) recently marched higher in response to a dividend payout raise and a forward-looking presentation. Management confirmed the annual revenue and earnings outlook it provided in October and issued guidance for the year ahead.
Pfizer Momentum Shift Makes Me Less Bullish (Technical Analysis)
Pfizer Inc.'s technical indicators have shifted from bullish to bearish, with the stock now trading below its 30-week EMA and showing bearish momentum. Volume analysis indicates recent institutional selling, and relative strength has deteriorated, underperforming the S&P 500 since July 2024. Pfizer stock is in a consolidation phase, potentially setting up for a bull run if it can recapture its 30-week EMA and show bullish volume.
Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations
Pfizer projects total revenues between $61.0 and $64.0 billion with EPS in the range of $2.80 to $3.00.
Is Pfizer Stock Undervalued?
Pfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 billion, and its adjusted earnings to be in the range of $2.80 and $3.00 per share.
Pfizer climbs 4% on 2025 outlook
Evan David Seigerman, BMO analyst, joins 'Closing Bell Overtime' to talk Pfizer's 2025 outlook.
Pfizer's 2025 guidance positions company for EPS expansion, says BMO
BMO Capital reiterated an Outperform rating and $36 price target on Pfizer, saying that 2025 guidance succeeds in meeting the majority of the firm's expectations outlined in its preview, positioning the company for earnings per share expansion. The company's guide only just missed the firm's midpoint sales expectation, though midpoint EPS expectations of $2.90 in 2025 show roughly 2% growth year-over-year, giving investors confidence that the company has turned over a new leaf financially, the analyst tells investors in a research note. The firm continues to believe the revenue guidance is conservative, especially for ex-COVID products, leaving room for future beats and raises to sustain shares throughout the year.
Here's why Pfizer (PFE) stock is surging
Pfizer (NYSE: PFE) shares rose nearly 3% to $25.98 in premarket trading on December 17 after the pharmaceutical giant released its 2025 financial guidance.
Stock Of The Day: Is Pfizer About To Break Out? Expect A New Uptrend If Resistance Breaks
Shares of Pfizer Inc. PFE are making a large move higher Tuesday. But the stock has run into resistance.
